S&P Futures
4,131.25 +7.75 (+0.19%) Dow Futures
33,949.00 +15.00 (+0.04%) Nasdaq Futures
12,563.25 +47.75 (+0.38%) Russell 2000 Futures
1,967.40 +2.30 (+0.12%) Crude Oil
75.50 +1.39 (+1.88%) Gold
1,887.40 +7.90 (+0.42%)
Tryp Therapeutics Inc. (TRYPF)
Chart Events
Performance Outlook
| Previous Close | 0.0750 |
| Open | 0.0700 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0750 - 0.0750 |
| 52 Week Range | 0.0400 - 0.1762 |
| Volume | |
| Avg. Volume | 46,150 |
| Market Cap | 7.231M |
| Beta (5Y Monthly) | -1.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for TRYPF
Related Research
- TRYP THERAPEUTICS INCWPM: Lowering target price to $36.00WHEATON PRECIOUS METALS CORP has an Investment Rating of SELL; a target price of $36.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.RatingFair ValueEconomic Moat6 days agoArgus Research
- ACCESSWIRE
Tryp Therapeutics Announces Interim Results for Its Phase II Clinical Trial for the Treatment of Binge Eating Disorder With Psilocybin-Assisted Psychotherapy
Tryp Therapeutics, Inc. (CSE:TRYP) (OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced interim results for the first five patients dosed in its Phase II STOP (Study of the Treatment of Overeating utilizing Psilocybin) trial.
- ACCESSWIRE
Tryp Therapeutics and Massachusetts General Hospital Sign Letter of Intent for Clinical Study Investigating the Use of Psilocybin-Assisted Psychotherapy for the Treatment of Patients Suffering From Irritable Bowel Syndrome (IBS)
Tryp Therapeutics, Inc. (CSE:TRYP) (OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced the signing of a letter of intent with Massachusetts General Hospital (MGH), the largest teaching hospital of Harvard Medical School, to fund and conduct a Phase 2a clinical trial investigating
- GlobeNewswire
Tryp Therapeutics to Present at Biotech Showcase on Monday, January 9, 2023
Company to be in San Francisco January 8-11, 2023, during 41st Annual J.P. Morgan Health Care ConferenceKELOWNA, British Columbia, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that the Company will be presenting at the Biotech Showcase on Monday, January 9, 2023, at the
